{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T16:48:19Z","timestamp":1793119699211,"version":"4.5.0"},"reference-count":153,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T00:00:00Z","timestamp":1716422400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T00:00:00Z","timestamp":1716422400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD) is a demyelinating disorder, distinct from multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD). MOGAD most frequently presents with optic neuritis (MOG-ON), often with characteristic clinical and radiological features. Bilateral involvement, disc swelling clinically and radiologically, and longitudinally extensive optic nerve hyperintensity with associated optic\u00a0perineuritis on MRI are key characteristics that can help distinguish MOG-ON from optic neuritis due to other aetiologies. The detection of serum MOG immunoglobulin G utilising a live cell-based assay in a patient with a compatible clinical phenotype is highly specific for the diagnosis of MOGAD. This review will highlight the key clinical and radiological features which expedite diagnosis, as well as ancillary investigations such as visual fields, visual evoked potentials and cerebrospinal fluid analysis, which may be less discriminatory. Optical coherence tomography can identify optic nerve swelling acutely, and atrophy chronically, and may transpire to have utility as a diagnostic and prognostic biomarker. MOG-ON appears to be largely responsive to corticosteroids, which are often the mainstay of acute management. However, relapses are common in patients in whom follow-up is prolonged, often in the context of early or rapid corticosteroid tapering. Establishing optimal acute therapy, the role of maintenance steroid-sparing immunotherapy for long-term relapse prevention, and identifying predictors of relapsing disease remain key research priorities in MOG-ON.<\/jats:p>","DOI":"10.1038\/s41433-024-03108-y","type":"journal-article","created":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T18:04:59Z","timestamp":1716487499000},"page":"2289-2301","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":82,"title":["MOG antibody-associated optic neuritis"],"prefix":"10.1038","volume":"38","author":[{"given":"Niroshan","family":"Jeyakumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Lerch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell C.","family":"Dale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0294-9768","authenticated-orcid":false,"given":"Sudarshini","family":"Ramanathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,23]]},"reference":[{"key":"3108_CR1","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/S1474-4422(22)00431-8","volume":"22","author":"B Banwell","year":"2023","unstructured":"Banwell B, Bennett JL, Marignier R, Kim HJ, Brilot F, Flanagan EP, et al. Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria. Lancet Neurol. 2023;22:268\u201382.","journal-title":"Lancet Neurol."},{"key":"3108_CR2","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/0165-5728(84)90064-X","volume":"6","author":"C Linnington","year":"1984","unstructured":"Linnington C, Webb M, Woodhams PL. A novel myelin-associated glycoprotein defined by a mouse monoclonal antibody. J Neuroimmunol. 1984;6:387\u201396.","journal-title":"J Neuroimmunol."},{"key":"3108_CR3","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1177\/1352458519845112","volume":"26","author":"CL de Mol","year":"2020","unstructured":"de Mol CL, Wong Y, van Pelt ED, Wokke B, Siepman T, Neuteboom RF, et al. The clinical spectrum and incidence of anti-MOG-associated acquired demyelinating syndromes in children and adults. Mult Scler. 2020;26:806\u201314.","journal-title":"Mult Scler."},{"key":"3108_CR4","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1136\/jnnp-2020-323158","volume":"91","author":"K O\u2019Connell","year":"2020","unstructured":"O\u2019Connell K, Hamilton-Shield A, Woodhall M, Messina S, Mariano R, Waters P, et al. Prevalence and incidence of neuromyelitis optica spectrum disorder, aquaporin-4 antibody-positive NMOSD and MOG antibody-positive disease in Oxfordshire, UK. J Neurol Neurosurg Psychiatry. 2020;91:1126\u20138.","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"3108_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1260358","volume":"14","author":"JY Hor","year":"2023","unstructured":"Hor JY, Fujihara K. Epidemiology of myelin oligodendrocyte glycoprotein antibody-associated disease: a review of prevalence and incidence worldwide. Front Neurol. 2023;14:1260358.","journal-title":"Front Neurol."},{"key":"3108_CR6","doi-asserted-by":"publisher","first-page":"3128","DOI":"10.1093\/brain\/awx276","volume":"140","author":"M Jurynczyk","year":"2017","unstructured":"Jurynczyk M, Messina S, Woodhall MR, Raza N, Everett R, Roca-Fernandez A, et al. Clinical presentation and prognosis in MOG-antibody disease: a UK study. Brain. 2017;140:3128\u201338.","journal-title":"Brain."},{"key":"3108_CR7","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1136\/jnnp-2017-316880","volume":"89","author":"S Ramanathan","year":"2018","unstructured":"Ramanathan S, Mohammad S, Tantsis E, Nguyen TK, Merheb V, Fung VSC, et al. Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination. J Neurol Neurosurg Psychiatry. 2018;89:127\u201337.","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"3108_CR8","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1001\/jamaneurol.2019.2940","volume":"77","author":"P Waters","year":"2020","unstructured":"Waters P, Fadda G, Woodhall M, O\u2019Mahony J, Brown RA, Castro DA, et al. Serial Anti-Myelin Oligodendrocyte Glycoprotein Antibody Analyses and Outcomes in Children With Demyelinating Syndromes. JAMA Neurol. 2020;77:82\u201393.","journal-title":"JAMA Neurol."},{"key":"3108_CR9","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1002\/acn3.51759","volume":"10","author":"JD Santoro","year":"2023","unstructured":"Santoro JD, Beukelman T, Hemingway C, Hokkanen SRK, Tennigkeit F, Chitnis T. Attack phenotypes and disease course in pediatric MOGAD. Ann Clin Transl Neurol. 2023;10:672\u201385.","journal-title":"Ann Clin Transl Neurol."},{"key":"3108_CR10","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1212\/01.WNL.0000147259.34163.33","volume":"63","author":"S Gaertner","year":"2004","unstructured":"Gaertner S, de Graaf KL, Greve B, Weissert R. Antibodies against glycosylated native MOG are elevated in patients with multiple sclerosis. Neurology. 2004;63:2381\u20133.","journal-title":"Neurology."},{"key":"3108_CR11","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1007\/s00415-006-0299-4","volume":"254","author":"J Kuhle","year":"2007","unstructured":"Kuhle J, Lindberg RL, Regeniter A, Mehling M, Hoffmann F, Reindl M, et al. Antimyelin antibodies in clinically isolated syndromes correlate with inflammation in MRI and CSF. J Neurol. 2007;254:160\u20138.","journal-title":"J Neurol"},{"key":"3108_CR12","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1056\/NEJMoa022328","volume":"349","author":"T Berger","year":"2003","unstructured":"Berger T, Rubner P, Schautzer F, Egg R, Ulmer H, Mayringer I, et al. Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. N Engl J Med. 2003;349:139\u201345.","journal-title":"N Engl J Med"},{"key":"3108_CR13","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1136\/jnnp.2005.077784","volume":"77","author":"S Rauer","year":"2006","unstructured":"Rauer S, Euler B, Reindl M, Berger T. Antimyelin antibodies and the risk of relapse in patients with a primary demyelinating event. J Neurol Neurosurg Psychiatry. 2006;77:739\u201342.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"3108_CR14","doi-asserted-by":"publisher","first-page":"9446","DOI":"10.1073\/pnas.1133443100","volume":"100","author":"C Breithaupt","year":"2003","unstructured":"Breithaupt C, Schubart A, Zander H, Skerra A, Huber R, Linington C, et al. Structural insights into the antigenicity of myelin oligodendrocyte glycoprotein. Proc Natl Acad Sci USA. 2003;100:9446\u201351.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3108_CR15","doi-asserted-by":"publisher","first-page":"17206","DOI":"10.1074\/jbc.M111.304246","volume":"287","author":"KL de Graaf","year":"2012","unstructured":"de Graaf KL, Albert M, Weissert R. Autoantigen conformation influences both B- and T-cell responses and encephalitogenicity. J Biol Chem. 2012;287:17206\u201313.","journal-title":"J Biol Chem"},{"key":"3108_CR16","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.autrev.2015.12.004","volume":"15","author":"S Ramanathan","year":"2016","unstructured":"Ramanathan S, Dale RC, Brilot F. Anti-MOG antibody: The history, clinical phenotype, and pathogenicity of a serum biomarker for demyelination. Autoimmun Rev. 2016;15:307\u201324.","journal-title":"Autoimmun Rev"},{"key":"3108_CR17","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/nm1488","volume":"13","author":"KC O\u2019Connor","year":"2007","unstructured":"O\u2019Connor KC, McLaughlin KA, De Jager PL, Chitnis T, Bettelli E, Xu C, et al. Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein. Nat Med. 2007;13:211\u20137.","journal-title":"Nat Med"},{"key":"3108_CR18","doi-asserted-by":"publisher","first-page":"4067","DOI":"10.4049\/jimmunol.0801888","volume":"183","author":"KA McLaughlin","year":"2009","unstructured":"McLaughlin KA, Chitnis T, Newcombe J, Franz B, Kennedy J, McArdel S, et al. Age-dependent B cell autoimmunity to a myelin surface antigen in pediatric multiple sclerosis. J Immunol. 2009;183:4067\u201376.","journal-title":"J Immunol"},{"key":"3108_CR19","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1002\/ana.21916","volume":"66","author":"F Brilot","year":"2009","unstructured":"Brilot F, Dale RC, Selter RC, Grummel V, Kalluri SR, Aslam M, et al. Antibodies to native myelin oligodendrocyte glycoprotein in children with inflammatory demyelinating central nervous system disease. Ann Neurol. 2009;66:833\u201342.","journal-title":"Ann Neurol"},{"key":"3108_CR20","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1212\/WNL.0b013e31826aac4e","volume":"79","author":"J Kitley","year":"2012","unstructured":"Kitley J, Woodhall M, Waters P, Leite MI, Devenney E, Craig J, et al. Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype. Neurology. 2012;79:1273\u20137.","journal-title":"Neurology"},{"key":"3108_CR21","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1212\/WNL.0000000000000101","volume":"82","author":"DK Sato","year":"2014","unstructured":"Sato DK, Callegaro D, Lana-Peixoto MA, Waters PJ, de Haidar Jorge FM, Takahashi T, et al. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology. 2014;82:474\u201381.","journal-title":"Neurology"},{"key":"3108_CR22","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000040","volume":"1","author":"S Ramanathan","year":"2014","unstructured":"Ramanathan S, Reddel SW, Henderson A, Parratt JD, Barnett M, Gatt PN, et al. Antibodies to myelin oligodendrocyte glycoprotein in bilateral and recurrent optic neuritis. Neurol Neuroimmunol Neuroinflamm. 2014;1:e40.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"3108_CR23","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1007\/s00401-020-02132-y","volume":"139","author":"R H\u00f6ftberger","year":"2020","unstructured":"H\u00f6ftberger R, Guo Y, Flanagan EP, Lopez-Chiriboga AS, Endmayr V, Hochmeister S, et al. The pathology of central nervous system inflammatory demyelinating disease accompanying myelin oligodendrocyte glycoprotein autoantibody. Acta Neuropathol. 2020;139:875\u201392.","journal-title":"Acta Neuropathol"},{"key":"3108_CR24","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1093\/brain\/awaa102","volume":"143","author":"Y Takai","year":"2020","unstructured":"Takai Y, Misu T, Kaneko K, Chihara N, Narikawa K, Tsuchida S, et al. Myelin oligodendrocyte glycoprotein antibody-associated disease: an immunopathological study. Brain. 2020;143:1431\u201346.","journal-title":"Brain"},{"key":"3108_CR25","doi-asserted-by":"publisher","first-page":"e0149411","DOI":"10.1371\/journal.pone.0149411","volume":"11","author":"K Kothur","year":"2016","unstructured":"Kothur K, Wienholt L, Tantsis EM, Earl J, Bandodkar S, Prelog K, et al. B Cell, Th17, and Neutrophil Related Cerebrospinal Fluid Cytokine\/Chemokines Are Elevated in MOG Antibody Associated Demyelination. PLoS One. 2016;11:e0149411.","journal-title":"PLoS One"},{"key":"3108_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102696","volume":"48","author":"PM Elsbernd","year":"2021","unstructured":"Elsbernd PM, Hoffman WR, Carter JL, Wingerchuk DM. Interleukin-6 inhibition with tocilizumab for relapsing MOG-IgG associated disorder (MOGAD): A case-series and review. Mult Scler Relat Disord. 2021;48:102696.","journal-title":"Mult Scler Relat Disord"},{"key":"3108_CR27","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1212\/NXI.0000000000000625","volume":"6","author":"S Winklmeier","year":"2019","unstructured":"Winklmeier S, Schl\u00fcter M, Spadaro M, Thaler FS, Vural A, Gerhards R, et al. Identification of circulating MOG-specific B cells in patients with MOG antibodies. Neurol Neuroimmunol Neuroinflamm. 2019;6:625.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"3108_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2019.101397","volume":"36","author":"X Li","year":"2019","unstructured":"Li X, Wang L, Zhou L, ZhangBao J, Miao MZ, Lu C, et al. The imbalance between regulatory and memory B cells accompanied by an increased number of circulating T-follicular helper cells in MOG-antibody-associated demyelination. Mult Scler Relat Disord. 2019;36:101397.","journal-title":"Mult Scler Relat Disord"},{"key":"3108_CR29","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.3389\/fimmu.2020.01188","volume":"11","author":"LS Hofer","year":"2020","unstructured":"Hofer LS, Ramberger M, Gredler V, Pescoller AS, Rost\u00e1sy K, Sospedra M, et al. Comparative Analysis of T-Cell Responses to Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein in Inflammatory Demyelinating Central Nervous System Diseases. Front Immunol. 2020;11:1188.","journal-title":"Front Immunol"},{"key":"3108_CR30","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/ana.25291","volume":"84","author":"M Spadaro","year":"2018","unstructured":"Spadaro M, Winklmeier S, Beltr\u00e1n E, Macrini C, H\u00f6ftberger R, Schuh E, et al. Pathogenicity of human antibodies against myelin oligodendrocyte glycoprotein. Ann Neurol. 2018;84:315\u201328.","journal-title":"Ann Neurol"},{"key":"3108_CR31","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1002\/ana.26226","volume":"90","author":"CW Keller","year":"2021","unstructured":"Keller CW, Lopez JA, Wendel E-M, Ramanathan S, Gross CC, Klotz L, et al. Complement Activation Is a Prominent Feature of MOGAD. Ann Neurol. 2021;90:976\u201382.","journal-title":"Ann Neurol"},{"key":"3108_CR32","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2300648120","volume":"120","author":"S Mader","year":"2023","unstructured":"Mader S, Ho S, Wong HK, Baier S, Winklmeier S, Riemer C, et al. Dissection of complement and Fc-receptor-mediated pathomechanisms of autoantibodies to myelin oligodendrocyte glycoprotein. Proc Natl Acad Sci USA. 2023;120:e2300648120.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3108_CR33","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/s41582-023-00776-4","volume":"19","author":"S Ramanathan","year":"2023","unstructured":"Ramanathan S, Brilot F, Irani SR, Dale RC. Origins and immunopathogenesis of autoimmune central nervous system disorders. Nat Rev Neurol. 2023;19:172\u201390.","journal-title":"Nat Rev Neurol"},{"key":"3108_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.nerep.2021.100033","volume":"1","author":"N Jeyakumar","year":"2021","unstructured":"Jeyakumar N, Waller S, Mahant N, Ramanathan S, Henderson APD. A case of CSF anti-MOG antibody-positive papillitis with intermediate uveitis in the setting of acute neurosyphilis. Neuroimmunol Rep. 2021;1:100033.","journal-title":"Neuroimmunol Rep"},{"key":"3108_CR35","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.jns.2017.09.011","volume":"382","author":"B-V Rusescu","year":"2017","unstructured":"Rusescu B-V, Diederich NJ, Tsobo C, Marignier R, Kerschen P. MOG antibody-associated optic neuritis in the setting of acute CMV infection. J Neurological Sci. 2017;382:44\u20136.","journal-title":"J Neurological Sci"},{"key":"3108_CR36","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1212\/WNL.0000000000202726","volume":"100","author":"F Mutete","year":"2023","unstructured":"Mutete F, Mwendaweli N, Asukile M. mulubwa s, Mumbi W, Saylor D. MOG Antibody-Associated Bilateral Optic Neuritis Associated with Johnson and Johnson COVID-19 Vaccination (P12-3.009). Neurology. 2023;100:2691.","journal-title":"Neurology."},{"key":"3108_CR37","volume":"8","author":"N Molazadeh","year":"2022","unstructured":"Molazadeh N, Bose G, Lotan I, Levy M. Autoimmune diseases and cancers overlapping with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): A systematic review. Mult Scler J Exp Transl Clin. 2022;8:20552173221128170.","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"3108_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2021.120044","volume":"432","author":"V Redenbaugh","year":"2022","unstructured":"Redenbaugh V, Flanagan EP, Floris V, Zara P, Bhatti MT, Sanchez F, et al. Exposure to TNF inhibitors is rare at MOGAD presentation. J Neurol Sci. 2022;432:120044.","journal-title":"J Neurol Sci"},{"key":"3108_CR39","doi-asserted-by":"publisher","DOI":"10.1126\/science.1260419","volume":"347","author":"M Uhl\u00e9n","year":"2015","unstructured":"Uhl\u00e9n M, Fagerberg L, Hallstr\u00f6m BM, Lindskog C, Oksvold P, Mardinoglu A, et al. Tissue-based map of the human proteome. Science. 2015;347:1260419.","journal-title":"Science"},{"key":"3108_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2023.106306","volume":"187","author":"I Boccuni","year":"2023","unstructured":"Boccuni I, Bas-Orth C, Bruehl C, Draguhn A, Fairless R. Glutamate transporter contribution to retinal ganglion cell vulnerability in a rat model of multiple sclerosis. Neurobiol Dis. 2023;187:106306.","journal-title":"Neurobiol Dis"},{"key":"3108_CR41","first-page":"895","volume":"42","author":"P Hofman","year":"2001","unstructured":"Hofman P, Hoyng P, vanderWerf F, Vrensen GF, Schlingemann RO. Lack of blood-brain barrier properties in microvessels of the prelaminar optic nerve head. Invest Ophthalmol Vis Sci. 2001;42:895\u2013901.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"3108_CR42","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-016-0718-0","volume":"13","author":"S Jarius","year":"2016","unstructured":"Jarius S, Ruprecht K, Kleiter I, Borisow N, Asgari N, Pitarokoili K, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflammation. 2016;13:280.","journal-title":"J Neuroinflammation"},{"key":"3108_CR43","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ajo.2018.07.020","volume":"195","author":"JJ Chen","year":"2018","unstructured":"Chen JJ, Flanagan EP, Jitprapaikulsan J, L\u00f3pez-Chiriboga ASS, Fryer JP, Leavitt JA, et al. Myelin Oligodendrocyte Glycoprotein Antibody-Positive Optic Neuritis: Clinical Characteristics, Radiologic Clues, and Outcome. Am J Ophthalmol. 2018;195:8\u201315.","journal-title":"Am J Ophthalmol"},{"key":"3108_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102718","volume":"48","author":"T Rempe","year":"2021","unstructured":"Rempe T, Tarhan B, Rodriguez E, Viswanathan VT, Gyang TV, Carlson A, et al. Anti-MOG associated disorder-Clinical and radiological characteristics compared to AQP4-IgG+ NMOSD-A single-center experience. Mult Scler Relat Disord. 2021;48:102718.","journal-title":"Mult Scler Relat Disord"},{"key":"3108_CR45","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1177\/1352458515593406","volume":"22","author":"S Ramanathan","year":"2015","unstructured":"Ramanathan S, Prelog K, Barnes EH, Tantsis EM, Reddel SW, Henderson APD, et al. Radiological differentiation of optic neuritis with myelin oligodendrocyte glycoprotein antibodies, aquaporin-4 antibodies, and multiple sclerosis. Mult Scler J. 2015;22:470\u201382.","journal-title":"Mult Scler J"},{"key":"3108_CR46","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/S1474-4422(22)00187-9","volume":"22","author":"JL Bennett","year":"2023","unstructured":"Bennett JL, Costello F, Chen JJ, Petzold A, Biousse V, Newman NJ, et al. Optic neuritis and autoimmune optic neuropathies: advances in diagnosis and treatment. Lancet Neurol. 2023;22:89\u2013100.","journal-title":"Lancet Neurol"},{"key":"3108_CR47","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1111\/ene.14089","volume":"27","author":"N Shor","year":"2020","unstructured":"Shor N, Aboab J, Maillart E, Lecler A, Bensa C, Le Guern G, et al. Clinical, imaging and follow-up study of optic neuritis associated with myelin oligodendrocyte glycoprotein antibody: a multicentre study of 62 adult patients. Eur J Neurol. 2020;27:384\u201391.","journal-title":"Eur J Neurol"},{"key":"3108_CR48","doi-asserted-by":"publisher","first-page":"4079","DOI":"10.2147\/OPTH.S288224","volume":"14","author":"C Narongkhananukul","year":"2020","unstructured":"Narongkhananukul C, Padungkiatsagul T, Jindahra P, Khongkhatithum C, Thampratankul L, Vanikieti K. MOG-IgG- versus AQP4-IgG-Positive Optic Neuritis in Thailand: Clinical Characteristics and Long-Term Visual Outcomes Comparison. Clin Ophthalmol. 2020;14:4079\u201388.","journal-title":"Clin Ophthalmol"},{"key":"3108_CR49","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1136\/bjophthalmol-2019-314845","volume":"104","author":"JB Ducloyer","year":"2020","unstructured":"Ducloyer JB, Caignard A, Aidaoui R, Ollivier Y, Plubeau G, Santos-Moskalyk S, et al. MOG-Ab prevalence in optic neuritis and clinical predictive factors for diagnosis. Br J Ophthalmol. 2020;104:842\u20135.","journal-title":"Br J Ophthalmol"},{"key":"3108_CR50","doi-asserted-by":"publisher","DOI":"10.3389\/fpain.2022.870211","volume":"3","author":"H Kang","year":"2022","unstructured":"Kang H, Qiu H, Hu X, Wei S, Tao Y. Differences in Neuropathic Pain and Radiological Features Between AQP4-ON, MOG-ON, and IDON. Front Pain Res. 2022;3:870211.","journal-title":"Front Pain Res"},{"key":"3108_CR51","doi-asserted-by":"publisher","first-page":"194","DOI":"10.4103\/ijo.IJO_887_21","volume":"70","author":"S Ambika","year":"2022","unstructured":"Ambika S, Durgapriyadarshini S, Padmalakshmi K, Noronha V, Arjundas D. Clinical profile, imaging features and short term visual outcomes of Indian optic neuritis patients with and without seromarkers for myelin oligodendrocyte glycoprotein and neuromyelitis optica. Indian J Ophthalmol. 2022;70:194\u2013200.","journal-title":"Indian J Ophthalmol"},{"key":"3108_CR52","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s13760-021-01712-3","volume":"122","author":"S Dauby","year":"2022","unstructured":"Dauby S, Dive D, Lutteri L, Andris C, Hansen I, Maquet P, et al. Comparative study of AQP4-NMOSD, MOGAD and seronegative NMOSD: a single-center Belgian cohort. Acta Neurol Belg. 2022;122:135\u201344.","journal-title":"Acta Neurol Belg"},{"key":"3108_CR53","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1007\/s00415-018-8956-y","volume":"265","author":"I Lotan","year":"2018","unstructured":"Lotan I, Brody J, Hellmann MA, Bialer O, Ganelin-Cohen E, Michaeli N, et al. Myelin oligodendrocyte glycoprotein-positive optic neuritis masquerading as pseudotumor cerebri at presentation. J Neurol. 2018;265:1985\u20138.","journal-title":"J Neurol"},{"key":"3108_CR54","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.msard.2018.10.003","volume":"27","author":"RN Narayan","year":"2019","unstructured":"Narayan RN, Wang C, Sguigna P, Husari K, Greenberg B. Atypical Anti-MOG syndrome with aseptic meningoencephalitis and pseudotumor cerebri-like presentations. Mult Scler Relat Disord. 2019;27:30\u20133.","journal-title":"Mult Scler Relat Disord"},{"key":"3108_CR55","doi-asserted-by":"publisher","first-page":"2322","DOI":"10.1111\/jpc.16189","volume":"58","author":"WK Wong","year":"2022","unstructured":"Wong WK, Troedson C, Peacock K, Brilot-Turville F, Menezes MP, Dale RC, et al. Steroid-responsive aseptic meningitis with raised intracranial pressure syndrome associated with myelin oligodendrocyte glycoprotein autoantibodies. J Paediatr Child Health. 2022;58:2322\u20136.","journal-title":"J Paediatr Child Health"},{"key":"3108_CR56","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.18240\/ijo.2022.07.09","volume":"15","author":"P Murtagh","year":"2022","unstructured":"Murtagh P, Coman A, Stephenson K, Gaughan M, Ryan D, McNeill G, et al. Neuromyelitis optica spectrum disorders and anti-myelin oligodendrocyte glycoprotein positive optic neuropathies. Int J Ophthalmol. 2022;15:1095\u2013107.","journal-title":"Int J Ophthalmol"},{"key":"3108_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.104237","volume":"68","author":"JJ Chen","year":"2022","unstructured":"Chen JJ, Flanagan EP, Bhatti MT, Tisavipat N, Jamali S, Kunchok A, et al. Details and outcomes of a large cohort of MOG-IgG associated optic neuritis. Mult Scler Relat Disord. 2022;68:104237.","journal-title":"Mult Scler Relat Disord"},{"key":"3108_CR58","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1007\/s00415-020-10097-x","volume":"268","author":"R Vicini","year":"2021","unstructured":"Vicini R, Br\u00fcgger D, Abegg M, Salmen A, Grabe HM. Differences in morphology and visual function of myelin oligodendrocyte glycoprotein antibody and multiple sclerosis associated optic neuritis. J Neurol. 2021;268:276\u201384.","journal-title":"J Neurol"},{"key":"3108_CR59","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1016\/S0161-6420(03)00477-9","volume":"110","author":"HE Fazzone","year":"2003","unstructured":"Fazzone HE, Lefton DR, Kupersmith MJ. Optic neuritis: correlation of pain and magnetic resonance imaging. Ophthalmology. 2003;110:1646\u20139.","journal-title":"Ophthalmology"},{"key":"3108_CR60","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.1007\/s10072-020-04371-z","volume":"41","author":"Y Jang","year":"2020","unstructured":"Jang Y, Kim SM, Yun YI, Lee HJ, Kim SJ, Jung JH, et al. Comparison between optic neuritis associated with antibody against myelin oligodendrocyte glycoprotein and presumed idiopathic optic perineuritis. Neurol Sci. 2020;41:2755\u201360.","journal-title":"Neurol Sci"},{"key":"3108_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.101965","volume":"40","author":"S Asseyer","year":"2020","unstructured":"Asseyer S, Hamblin J, Messina S, Mariano R, Siebert N, Everett R, et al. Prodromal headache in MOG-antibody positive optic neuritis. Mult Scler Relat Disord. 2020;40:101965.","journal-title":"Mult Scler Relat Disord"},{"key":"3108_CR62","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1136\/bjophthalmol-2017-311177","volume":"102","author":"Y Zhao","year":"2018","unstructured":"Zhao Y, Tan S, Chan TCY, Xu Q, Zhao J, Teng D, et al. Clinical features of demyelinating optic neuritis with seropositive myelin oligodendrocyte glycoprotein antibody in Chinese patients. Br J Ophthalmol. 2018;102:1372\u20137.","journal-title":"Br J Ophthalmol"},{"key":"3108_CR63","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1111\/ene.13932","volume":"26","author":"S Ramanathan","year":"2019","unstructured":"Ramanathan S, Fraser C, Curnow SR, Ghaly M, Leventer RJ, Lechner-Scott J, et al. Uveitis and optic perineuritis in the context of myelin oligodendrocyte glycoprotein antibody seropositivity. Eur J Neurol. 2019;26:1137\u2013e75.","journal-title":"Eur J Neurol"},{"key":"3108_CR64","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/01658107.2019.1607883","volume":"44","author":"AS Lopez-Chiriboga","year":"2020","unstructured":"Lopez-Chiriboga AS, Van Stavern G, Flanagan EP, Pittock SJ, Fryer J, Bhatti MT, et al. Myelin Oligodendrocyte Glycoprotein Antibody (MOG-IgG)-Positive Optic Perineuritis. Neuroophthalmology. 2020;44:1\u20134.","journal-title":"Neuroophthalmology"},{"key":"3108_CR65","volume":"6","author":"P Gupta","year":"2020","unstructured":"Gupta P, Goyal V, Srivastava AK, Pandit AK, Prasad K. Uveitis, optic neuritis and MOG. Mult Scler J Exp Transl Clin. 2020;6:2055217320925107.","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"3108_CR66","doi-asserted-by":"publisher","first-page":"e753","DOI":"10.1111\/aos.14054","volume":"97","author":"R Deschamps","year":"2019","unstructured":"Deschamps R, Vasseur V, Shor N, Vignal C, Salomon L, Gout O, et al. A new association: acute macular neuroretinopathy in acute optic neuritis. Acta Ophthalmologica. 2019;97:e753\u2013e6.","journal-title":"Acta Ophthalmologica"},{"key":"3108_CR67","doi-asserted-by":"publisher","first-page":"3307","DOI":"10.2169\/internalmedicine.9840-17","volume":"57","author":"T Kon","year":"2018","unstructured":"Kon T, Hikichi H, Ueno T, Suzuki C, Nunomura J, Kaneko K, et al. Myelin Oligodendrocyte Glycoprotein-IgG-positive Recurrent Bilateral Optic Papillitis with Serous Retinal Detachment. Intern Med. 2018;57:3307\u201312.","journal-title":"Intern Med"},{"key":"3108_CR68","doi-asserted-by":"crossref","unstructured":"Mittal A, Baig IF, Merchant AG, Chen JJ, Choi JJ, Goldberg A, et al. Sj\u00f6gren Disease and Myelin Oligodendrocyte Glycoprotein Antibody\u2013Associated Optic Neuritis. J Neuro Ophthalmol. 2021;41:e48\u2013e50.","DOI":"10.1097\/WNO.0000000000000945"},{"key":"3108_CR69","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1016\/j.ophtha.2019.07.004","volume":"126","author":"G Budoff","year":"2019","unstructured":"Budoff G, Bhagat N, Frohman L. Anti-Myelin Oligodendrocyte Glycoprotein Optic Neuritis Presenting with Dense Premacular Hemorrhage. Ophthalmology. 2019;126:1639.","journal-title":"Ophthalmology"},{"key":"3108_CR70","doi-asserted-by":"crossref","unstructured":"Wagley S, Wang Y, McClelland CM, Chen JJ, Lee MS. Myelin Oligodendrocyte Glycoprotein Antibody-Positive Optic Neuritis Presenting as Idiopathic Orbital Inflammatory Syndrome. J Neuro Ophthalmol. 2021;41:e46\u2013e47.","DOI":"10.1097\/WNO.0000000000000918"},{"key":"3108_CR71","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1080\/01658107.2019.1571089","volume":"44","author":"S Kurathong","year":"2019","unstructured":"Kurathong S, Sanpatchayapong A, Apiwattanakul M. Case Report: Anti-myelin Oligodendrocyte Glycoprotein (MOG) Positive in a Patient Presented with Orbital Apex Syndrome. Neuroophthalmology. 2019;44:255\u20137.","journal-title":"Neuroophthalmology"},{"key":"3108_CR72","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1212\/WNL.52.1.179","volume":"52","author":"B Val\u00e9rie","year":"1999","unstructured":"Val\u00e9rie B, Claudine T, Etienne B-M, Etienne R. Multiple sclerosis associated with uveitis in two large clinic-based series. Neurology. 1999;52:179.","journal-title":"Neurology."},{"key":"3108_CR73","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1177\/1352458514539782","volume":"21","author":"E Shugaiv","year":"2015","unstructured":"Shugaiv E, T\u00fcz\u00fcn E, K\u00fcrt\u00fcnc\u00fc M, K\u0131yat-Atamer A, \u00c7oban A, Akman-Demir G, et al. Uveitis as a prognostic factor in multiple sclerosis. Mult Scler. 2015;21:105\u20137.","journal-title":"Mult Scler"},{"key":"3108_CR74","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1001\/jamaneurol.2017.4601","volume":"75","author":"Y Hacohen","year":"2018","unstructured":"Hacohen Y, Wong YY, Lechner C, Jurynczyk M, Wright S, Konuskan B, et al. Disease Course and Treatment Responses in Children With Relapsing Myelin Oligodendrocyte Glycoprotein Antibody\u2013Associated Disease. JAMA Neurol. 2018;75:478\u201387.","journal-title":"JAMA Neurol"},{"key":"3108_CR75","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1002\/ana.25909","volume":"89","author":"A Cobo-Calvo","year":"2021","unstructured":"Cobo-Calvo A, Ruiz A, Rollot F, Arrambide G, Deschamps R, Maillart E, et al. Clinical Features and Risk of Relapse in Children and Adults with Myelin Oligodendrocyte Glycoprotein Antibody\u2013Associated Disease. Ann Neurol. 2021;89:30\u201341.","journal-title":"Ann Neurol"},{"key":"3108_CR76","doi-asserted-by":"publisher","first-page":"960","DOI":"10.3389\/fneur.2020.00960","volume":"11","author":"E Parrotta","year":"2020","unstructured":"Parrotta E, Kister I. The Expanding Clinical Spectrum of Myelin Oligodendrocyte Glycoprotein (MOG) Antibody Associated Disease in Children and Adults. Front Neurol. 2020;11:960.","journal-title":"Front Neurol"},{"key":"3108_CR77","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1080\/08820538.2020.1866027","volume":"35","author":"A Winter","year":"2020","unstructured":"Winter A, Chwalisz B. MRI Characteristics of NMO, MOG and MS Related Optic Neuritis. Semin Ophthalmol. 2020;35:333\u201342.","journal-title":"Semin Ophthalmol"},{"key":"3108_CR78","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1016\/S0161-6420(02)01148-X","volume":"109","author":"JF Rizzo","year":"2002","unstructured":"Rizzo JF, Andreoli CM, Rabinov JD. Use of magnetic resonance imaging to differentiate optic neuritis and nonarteritic anterior ischemic optic neuropathy. Ophthalmology. 2002;109:1679\u201384.","journal-title":"Ophthalmology"},{"key":"3108_CR79","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.msard.2019.01.021","volume":"29","author":"S Salama","year":"2019","unstructured":"Salama S, Khan M, Levy M, Izbudak I. Radiological characteristics of myelin oligodendrocyte glycoprotein antibody disease. Mult Scler Relat Disord. 2019;29:15\u201322.","journal-title":"Mult Scler Relat Disord"},{"key":"3108_CR80","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.103118","volume":"54","author":"T Carandini","year":"2021","unstructured":"Carandini T, Sacchi L, Bovis F, Azzimonti M, Bozzali M, Galimberti D, et al. Distinct patterns of MRI lesions in MOG antibody disease and AQP4 NMOSD: a systematic review and meta-analysis. Mult Scler Relat Disord. 2021;54:103118.","journal-title":"Mult Scler Relat Disord"},{"key":"3108_CR81","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1177\/13524585211011450","volume":"28","author":"D Tajfirouz","year":"2022","unstructured":"Tajfirouz D, Padungkiatsagul T, Beres S, Moss HE, Pittock S, Flanagan E, et al. Optic chiasm involvement in AQP-4 antibody-positive NMO and MOG antibody-associated disorder. Mult Scler. 2022;28:149\u201353.","journal-title":"Mult Scler"},{"key":"3108_CR82","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2019.116430","volume":"405","author":"C Chen","year":"2019","unstructured":"Chen C, Liu C, Fang L, Zou Y, Ruan H, Wang Y, et al. Different magnetic resonance imaging features between MOG antibody- and AQP4 antibody-mediated disease: A Chinese cohort study. J Neurol Sci. 2019;405:116430.","journal-title":"J Neurol Sci"},{"key":"3108_CR83","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1177\/1352458519893093","volume":"26","author":"S Salama","year":"2020","unstructured":"Salama S, Khan M, Shanechi A, Levy M, Izbudak I. MRI differences between MOG antibody disease and AQP4 NMOSD. Mult Scler. 2020;26:1854\u201365.","journal-title":"Mult Scler"},{"key":"3108_CR84","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1001\/archopht.119.9.1299","volume":"119","author":"V Purvin","year":"2001","unstructured":"Purvin V, Kawasaki A, Jacobson DM. Optic perineuritis: clinical and radiographic features. Arch Ophthalmol. 2001;119:1299\u2013306.","journal-title":"Arch Ophthalmol"},{"key":"3108_CR85","doi-asserted-by":"publisher","first-page":"e163-e","DOI":"10.1212\/NXI.0000000000000163","volume":"2","author":"S-M Kim","year":"2015","unstructured":"Kim S-M, Woodhall MR, Kim J-S, Kim S-J, Park KS, Vincent A, et al. Antibodies to MOG in adults with inflammatory demyelinating disease of the CNS. Neurol Neuroimmunol Neuroinflammation. 2015;2:e163-e.","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"key":"3108_CR86","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2019.101444","volume":"38","author":"M Yanagidaira","year":"2020","unstructured":"Yanagidaira M, Hattori T, Emoto H, Kiyosawa M, Yokota T. Optic perineuritis with anti-myelin oligodendrocyte glycoprotein antibody. Mult Scler Relat Disord. 2020;38:101444.","journal-title":"Mult Scler Relat Disord"},{"key":"3108_CR87","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2021.120035","volume":"430","author":"JS Xie","year":"2021","unstructured":"Xie JS, Donaldson L, Margolin E. Optic perineuritis: A Canadian case series and literature review. J Neurol Sci. 2021;430:120035.","journal-title":"J Neurol Sci"},{"key":"3108_CR88","volume":"15","author":"FN Sulaiman","year":"2023","unstructured":"Sulaiman FN, Kamardin NF, Sultan Abdul Kader MI, Ch\u2019ng H, Wan Abdul Halim WH. Myelin Oligodendrocyte Glycoprotein Optic Neuritis Presenting With Orbital Apex Syndrome. Cureus. 2023;15:e38975.","journal-title":"Cureus"},{"key":"3108_CR89","doi-asserted-by":"publisher","first-page":"213","DOI":"10.3109\/01658107.2015.1072726","volume":"39","author":"R Matsuda","year":"2015","unstructured":"Matsuda R, Kezuka T, Umazume A, Okunuki Y, Goto H, Tanaka K. Clinical Profile of Anti-Myelin Oligodendrocyte Glycoprotein Antibody Seropositive Cases of Optic Neuritis. Neuro Ophthalmol. 2015;39:213\u20139.","journal-title":"Neuro Ophthalmol"},{"key":"3108_CR90","doi-asserted-by":"publisher","first-page":"e0170847-e","DOI":"10.1371\/journal.pone.0170847","volume":"12","author":"H Stiebel-Kalish","year":"2017","unstructured":"Stiebel-Kalish H, Lotan I, Brody J, Chodick G, Bialer O, Marignier R, et al. Retinal Nerve Fiber Layer May Be Better Preserved in MOG-IgG versus AQP4-IgG Optic Neuritis: A Cohort Study. PloS One. 2017;12:e0170847-e.","journal-title":"PloS One"},{"key":"3108_CR91","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.103525","volume":"58","author":"JJ Chen","year":"2022","unstructured":"Chen JJ, Sotirchos ES, Henderson AD, Vasileiou ES, Flanagan EP, Bhatti MT, et al. OCT retinal nerve fiber layer thickness differentiates acute optic neuritis from MOG antibody-associated disease and Multiple Sclerosis: RNFL thickening in acute optic neuritis from MOGAD vs MS. Mult Scler Relat Disord. 2022;58:103525.","journal-title":"Mult Scler Relat Disord"},{"key":"3108_CR92","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.540156","volume":"11","author":"AG Filippatou","year":"2020","unstructured":"Filippatou AG, Mukharesh L, Saidha S, Calabresi PA, Sotirchos ES. AQP4-IgG and MOG-IgG Related Optic Neuritis\u2014Prevalence, Optical Coherence Tomography Findings, and Visual Outcomes: A Systematic Review and Meta-Analysis. Front Neurol. 2020;11:540156.","journal-title":"Front Neurol"},{"key":"3108_CR93","volume":"7","author":"S Barnes","year":"2021","unstructured":"Barnes S, You Y, Shen T, Hardy TA, Fraser C, Reddel SW, et al. Structural and functional markers of optic nerve damage in myelin oligodendrocyte glycoprotein antibody-associated optic neuritis. Mult Scler J Exp Transl Clin. 2021;7:20552173211063126.","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"3108_CR94","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-016-0720-6","volume":"13","author":"F Pache","year":"2016","unstructured":"Pache F, Zimmermann H, Mikolajczak J, Schumacher S, Lacheta A, Oertel FC, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 4: Afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients. J Neuroinflammation. 2016;13:282.","journal-title":"J Neuroinflammation"},{"key":"3108_CR95","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2022.120269","volume":"437","author":"T Akaishi","year":"2022","unstructured":"Akaishi T, Himori N, Takeshita T, Misu T, Takahashi T, Takai Y, et al. Follow-up of retinal thickness and optic MRI after optic neuritis in anti-MOG antibody-associated disease and anti-AQP4 antibody-positive NMOSD. J Neurol Sci. 2022;437:120269.","journal-title":"J Neurol Sci"},{"key":"3108_CR96","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.ncl.2016.08.012","volume":"35","author":"F Costello","year":"2017","unstructured":"Costello F. Optical Coherence Tomography in Neuro-ophthalmology. Neurol Clin. 2017;35:153\u201363.","journal-title":"Neurol Clin"},{"key":"3108_CR97","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1177\/1352458520937281","volume":"27","author":"R Deschamps","year":"2021","unstructured":"Deschamps R, Philibert M, Lamirel C, Lambert J, Vasseur V, Gueguen A, et al. Visual field loss and structure-function relationships in optic neuritis associated with myelin oligodendrocyte glycoprotein antibody. Mult Scler. 2021;27:855\u201363.","journal-title":"Mult Scler"},{"key":"3108_CR98","doi-asserted-by":"publisher","first-page":"4874","DOI":"10.1007\/s00415-021-10609-3","volume":"268","author":"J Yu","year":"2021","unstructured":"Yu J, Huang Y, Zhou L, ZhangBao J, Zong Y, Quan C, et al. Comparison of the retinal vascular network and structure in patients with optic neuritis associated with myelin oligodendrocyte glycoprotein or aquaporin-4 antibodies: an optical coherence tomography angiography study. J Neurol. 2021;268:4874\u201381.","journal-title":"J Neurol"},{"key":"3108_CR99","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-022-02848-2","volume":"22","author":"Y Yao","year":"2022","unstructured":"Yao Y, Li X, Xu Y, Liang X, Yang L, Shi FD, et al. The difference of the retinal structural and microvascular characteristics in patients with MOGAD-ON and AQP4-ON. BMC Neurol. 2022;22:323.","journal-title":"BMC Neurol"},{"key":"3108_CR100","doi-asserted-by":"publisher","first-page":"e424","DOI":"10.1097\/WNO.0000000000001116","volume":"41","author":"J Yu","year":"2021","unstructured":"Yu J, Huang Y, Quan C, Zhou L, ZhangBao J, Wu K, et al. Alterations in the Retinal Vascular Network and Structure in MOG Antibody-Associated Disease: An Optical Coherence Tomography Angiography Study. J Neuroophthalmol. 2021;41:e424\u2013e32.","journal-title":"J Neuroophthalmol"},{"key":"3108_CR101","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-020-01824-2","volume":"17","author":"S Jarius","year":"2020","unstructured":"Jarius S, Pellkofer H, Siebert N, Korporal-Kuhnke M, Hummert MW, Ringelstein M, et al. Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 1: Results from 163 lumbar punctures in 100 adult patients. J Neuroinflammation. 2020;17:261.","journal-title":"J Neuroinflammation"},{"key":"3108_CR102","doi-asserted-by":"publisher","first-page":"e674-e","DOI":"10.1212\/NXI.0000000000000674","volume":"7","author":"M Reindl","year":"2020","unstructured":"Reindl M, Schanda K, Woodhall M, Tea F, Ramanathan S, Sagen J, et al. International multicenter examination of MOG antibody assays. Neurol Neuroimmunol Neuroinflammation. 2020;7:e674-e.","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"key":"3108_CR103","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-019-0786-3","volume":"7","author":"F Tea","year":"2019","unstructured":"Tea F, Lopez JA, Ramanathan S, Merheb V, Lee FXZ, Zou A, et al. Characterization of the human myelin oligodendrocyte glycoprotein antibody response in demyelination. Acta Neuropathologica Commun. 2019;7:145.","journal-title":"Acta Neuropathologica Commun"},{"key":"3108_CR104","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1093\/jalm\/jfab101","volume":"7","author":"JA Lopez","year":"2022","unstructured":"Lopez JA, Houston SD, Tea F, Merheb V, Lee FXZ, Smith S, et al. Validation of a Flow Cytometry Live Cell-Based Assay to Detect Myelin Oligodendrocyte Glycoprotein Antibodies for Clinical Diagnostics. J Appl Lab Med. 2022;7:12\u201325.","journal-title":"J Appl Lab Med"},{"key":"3108_CR105","doi-asserted-by":"crossref","unstructured":"Kwon YN, Kim B, Kim JS, Mo H, Choi K, Oh SI, et al. Myelin Oligodendrocyte Glycoprotein-Immunoglobulin G in the CSF: Clinical Implication of Testing and Association With Disability. Neurol Neuroimmunol Neuroinflamm. 2022;9:e1095.","DOI":"10.1212\/NXI.0000000000001095"},{"key":"3108_CR106","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1136\/jnnp-2021-326779","volume":"93","author":"S Pace","year":"2022","unstructured":"Pace S, Orrell M, Woodhall M, Palace J, Leite MI, Irani SR, et al. Frequency of MOG-IgG in cerebrospinal fluid versus serum. J Neurol Neurosurg Psychiatry. 2022;93:334\u20135.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"3108_CR107","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/S1474-4422(21)00247-7","volume":"20","author":"RC Dale","year":"2021","unstructured":"Dale RC, Ramanathan S. Clinical decision making in MOG antibody-associated disease. Lancet Neurol. 2021;20:695\u20137.","journal-title":"Lancet Neurol"},{"key":"3108_CR108","doi-asserted-by":"publisher","first-page":"3938","DOI":"10.1093\/brain\/awad122","volume":"146","author":"Y Matsumoto","year":"2023","unstructured":"Matsumoto Y, Kaneko K, Takahashi T, Takai Y, Namatame C, Kuroda H, et al. Diagnostic implications of MOG-IgG detection in sera and cerebrospinal fluids. Brain. 2023;146:3938\u201348.","journal-title":"Brain"},{"key":"3108_CR109","doi-asserted-by":"publisher","first-page":"e1095","DOI":"10.1212\/WNL.0000000000201662","volume":"100","author":"S Carta","year":"2023","unstructured":"Carta S, Cobo Calvo \u00c1, Armangu\u00e9 T, Saiz A, Lechner C, Rost\u00e1sy K, et al. Significance of Myelin Oligodendrocyte Glycoprotein Antibodies in CSF: A Retrospective Multicenter Study. Neurology. 2023;100:e1095\u2013e108.","journal-title":"Neurology"},{"key":"3108_CR110","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1016\/S1474-4422(22)00200-9","volume":"21","author":"A Petzold","year":"2022","unstructured":"Petzold A, Fraser CL, Alroughani R, Alshowaeir D, Alvarenga R, Andris C, et al. Diagnosis and classification of optic neuritis. Lancet Neurol. 2022;21:1120\u201334.","journal-title":"Lancet Neurol"},{"key":"3108_CR111","doi-asserted-by":"publisher","first-page":"15986","DOI":"10.3390\/ijms242115986","volume":"24","author":"G Greco","year":"2023","unstructured":"Greco G, Colombo E, Gastaldi M, Ahmad L, Tavazzi E, Bergamaschi R, et al. Beyond Myelin Oligodendrocyte Glycoprotein and Aquaporin-4 Antibodies: Alternative Causes of Optic Neuritis. Int J Mol Sci. 2023;24:15986.","journal-title":"Int J Mol Sci"},{"key":"3108_CR112","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1001\/jamaneurol.2016.2549","volume":"73","author":"B Fang","year":"2016","unstructured":"Fang B, McKeon A, Hinson SR, Kryzer TJ, Pittock SJ, Aksamit AJ, et al. Autoimmune Glial Fibrillary Acidic Protein Astrocytopathy: A Novel Meningoencephalomyelitis. JAMA Neurol. 2016;73:1297\u2013307.","journal-title":"JAMA Neurol"},{"key":"3108_CR113","doi-asserted-by":"crossref","unstructured":"Chen JJ, Aksamit AJ, McKeon A, Pittock SJ, Weinshenker BG, Leavitt JA, et al. Optic Disc Edema in Glial Fibrillary Acidic Protein Autoantibody\u2013Positive Meningoencephalitis. J Neuro Ophthalmol. 2018;38:276\u201381.","DOI":"10.1097\/WNO.0000000000000593"},{"key":"3108_CR114","doi-asserted-by":"crossref","unstructured":"Wang S, Hou H, Tang Y, Zhang S, Wang G, Guo Z, et al. An overview on CV2\/CRMP5 antibody-associated paraneoplastic neurological syndromes. Neural Regen Res. 2023;18:2357\u201364.","DOI":"10.4103\/1673-5374.371400"},{"key":"3108_CR115","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1002\/ana.10587","volume":"54","author":"SA Cross","year":"2003","unstructured":"Cross SA, Salomao DR, Parisi JE, Kryzer TJ, Bradley EA, Mines JA, et al. Paraneoplastic autoimmune optic neuritis with retinitis defined by CRMP-5-IgG. Ann Neurol. 2003;54:38\u201350.","journal-title":"Ann Neurol"},{"key":"3108_CR116","unstructured":"Kaushik M, Virdee J, Giridharan S, Chavda SV, Batra R. Response of Recoverin-Positive Optic Neuritis to Chemotherapy, Steroid, and Plasma Exchange. Journal of neuro-ophthalmology. 2024;44:e79\u2013e81."},{"key":"3108_CR117","doi-asserted-by":"publisher","first-page":"104694","DOI":"10.1016\/j.msard.2023.104694","volume":"73","author":"E Erda\u011f","year":"2023","unstructured":"Erda\u011f E, Emekli AS, G\u00fcnd\u00fcz T, K\u00fc\u00e7\u00fckali C\u0130, K\u00fcrt\u00fcnc\u00fc M, T\u00fcz\u00fcn E. Serum IgG of patients with relapsing inflammatory optic neuropathy immunoreacts with Sox2-positive glial cells of the optic nerve. Mult Scler Relat Disord. 2023;73:104694.","journal-title":"Mult Scler Relat Disord."},{"key":"3108_CR118","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1093\/brain\/awu142","volume":"137","author":"A Carvajal-Gonz\u00e1lez","year":"2014","unstructured":"Carvajal-Gonz\u00e1lez A, Leite MI, Waters P, Woodhall M, Coutinho E, Balint B, et al. Glycine receptor antibodies in PERM and related syndromes: characteristics, clinical features and outcomes. Brain. 2014;137:2178\u201392.","journal-title":"Brain"},{"key":"3108_CR119","doi-asserted-by":"publisher","first-page":"e270","DOI":"10.1212\/NXI.0000000000000270","volume":"3","author":"PK Desmond","year":"2016","unstructured":"Desmond PK, Ben JB, Elizabeth MG, Gordon TP. Optic neuropathy associated with systemic sarcoidosis. Neurol Neuroimmunol Neuroinflammation. 2016;3:e270.","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"key":"3108_CR120","first-page":"85","volume":"20","author":"D Kidd","year":"2003","unstructured":"Kidd D, Beynon HL. The neurological complications of systemic sarcoidosis. Sarcoidosis Vasc Diffus Lung Dis. 2003;20:85\u201394.","journal-title":"Sarcoidosis Vasc Diffus Lung Dis"},{"key":"3108_CR121","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1177\/1352458517699791","volume":"24","author":"N Asgari","year":"2018","unstructured":"Asgari N, Jarius S, Laustrup H, Skejoe HPB, Lillevang ST, Weinshenker BG, et al. Aquaporin-4-autoimmunity in patients with systemic lupus erythematosus: A predominantly population-based study. Mult Scler. 2018;24:331\u20139.","journal-title":"Mult Scler"},{"key":"3108_CR122","first-page":"59","volume":"7","author":"R Kahloun","year":"2015","unstructured":"Kahloun R, Abroug N, Ksiaa I, Mahmoud A, Zeghidi H, Zaouali S, et al. Infectious optic neuropathies: a clinical update. Eye Brain. 2015;7:59\u201381.","journal-title":"Eye Brain"},{"key":"3108_CR123","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/S0002-9394(14)76784-4","volume":"111","author":"NJ Newman","year":"1991","unstructured":"Newman NJ, Lott MT, Wallace DC. The clinical characteristics of pedigrees of Leber\u2019s hereditary optic neuropathy with the 11778 mutation. Am J Ophthalmol. 1991;111:750\u201362.","journal-title":"Am J Ophthalmol"},{"key":"3108_CR124","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1097\/WNO.0000000000000853","volume":"40","author":"S Raviskanthan","year":"2020","unstructured":"Raviskanthan S, Perera N, Fok A. Recurrent Bilateral Myelin Oligodendrocyte Glycoprotein Antibody Optic Neuritis in a Leber Hereditary Optic Neuropathy Carrier. J Neuro Ophthalmol. 2020;40:246\u20137.","journal-title":"J Neuro Ophthalmol"},{"key":"3108_CR125","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1093\/brain\/awg045","volume":"126","author":"D Kidd","year":"2003","unstructured":"Kidd D, Burton B, Plant GT, Graham EM. Chronic relapsing inflammatory optic neuropathy (CRION). Brain. 2003;126:276\u201384.","journal-title":"Brain"},{"key":"3108_CR126","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1136\/jnnp-2019-320493","volume":"90","author":"A Petzold","year":"2019","unstructured":"Petzold A, Woodhall M, Khaleeli Z, Tobin WO, Pittock SJ, Weinshenker BG, et al. Aquaporin-4 and myelin oligodendrocyte glycoprotein antibodies in immune-mediated optic neuritis at long-term follow-up. J Neurol Neurosurg Psychiatry. 2019;90:1021\u20136.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"3108_CR127","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-018-1335-x","volume":"15","author":"H-J Lee","year":"2018","unstructured":"Lee H-J, Kim B, Waters P, Woodhall M, Irani S, Ahn S, et al. Chronic relapsing inflammatory optic neuropathy (CRION): a manifestation of myelin oligodendrocyte glycoprotein antibodies. J Neuroinflammation. 2018;15:302.","journal-title":"J Neuroinflammation"},{"key":"3108_CR128","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1136\/jnnp.2008.146894","volume":"81","author":"A Petzold","year":"2010","unstructured":"Petzold A, Pittock S, Lennon V, Maggiore C, Weinshenker BG, Plant GT. Neuromyelitis optica-IgG (aquaporin-4) autoantibodies in immune mediated optic neuritis. J Neurol Neurosurg Psychiatry. 2010;81:109\u201311.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"3108_CR129","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1001\/jamaneurol.2013.5857","volume":"71","author":"J Kitley","year":"2014","unstructured":"Kitley J, Waters P, Woodhall M, Leite MI, Murchison A, George J, et al. Neuromyelitis Optica Spectrum Disorders With Aquaporin-4 and Myelin-Oligodendrocyte Glycoprotein Antibodies: A Comparative Study. JAMA Neurol. 2014;71:276\u201383.","journal-title":"JAMA Neurol"},{"key":"3108_CR130","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1177\/1352458518811597","volume":"25","author":"LM Oliveira","year":"2019","unstructured":"Oliveira LM, Ap\u00f3stolos-Pereira SL, Pitombeira MS, Bruel Torretta PH, Callegaro D, Sato DK. Persistent MOG-IgG positivity is a predictor of recurrence in MOG-IgG-associated optic neuritis, encephalitis and myelitis. Mult Scler. 2019;25:1907\u201314.","journal-title":"Mult Scler"},{"key":"3108_CR131","doi-asserted-by":"publisher","first-page":"e2142780-e","DOI":"10.1001\/jamanetworkopen.2021.42780","volume":"5","author":"C Satukijchai","year":"2022","unstructured":"Satukijchai C, Mariano R, Messina S, Sa M, Woodhall MR, Robertson NP, et al. Factors Associated With Relapse and Treatment of Myelin Oligodendrocyte Glycoprotein Antibody\u2013Associated Disease in the United Kingdom. JAMA Netw Open. 2022;5:e2142780-e.","journal-title":"JAMA Netw Open"},{"key":"3108_CR132","doi-asserted-by":"publisher","first-page":"e200035","DOI":"10.1212\/NXI.0000000000200035","volume":"9","author":"EM Wendel","year":"2022","unstructured":"Wendel EM, Thonke HS, Bertolini A, Baumann M, Blaschek A, Merkenschlager A, et al. Temporal Dynamics of MOG Antibodies in Children With Acquired Demyelinating Syndrome. Neurol Neuroimmunol Neuroinflammation. 2022;9:e200035.","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"key":"3108_CR133","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1212\/WNL.94.15_supplement.862","volume":"94","author":"A Budhram","year":"2020","unstructured":"Budhram A, Kunchok A, Flanagan E. Adding FUEL to the FLAMES: FLAIR-variable Unilateral Enhancement of the Leptomeninges (FUEL) in MOG-IgG-Associated Disease (862). Neurology. 2020;94:862. 15_supplement","journal-title":"Neurology"},{"key":"3108_CR134","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1111\/ene.13602","volume":"25","author":"YYM Wong","year":"2018","unstructured":"Wong YYM, Hacohen Y, Armangue T, Wassmer E, Verhelst H, Hemingway C, et al. Paediatric acute disseminated encephalomyelitis followed by optic neuritis: disease course, treatment response and outcome. Eur J Neurol. 2018;25:782\u20136.","journal-title":"Eur J Neurol"},{"key":"3108_CR135","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1007\/s00415-012-6441-6","volume":"259","author":"IA Ketelslegers","year":"2012","unstructured":"Ketelslegers IA, Catsman-Berrevoets CE, Neuteboom RF, Boon M, van Dijk KG, Eikelenboom MJ, et al. Incidence of acquired demyelinating syndromes of the CNS in Dutch children: a nationwide study. J Neurol. 2012;259:1929\u201335.","journal-title":"J Neurol"},{"key":"3108_CR136","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1002\/ana.26731","volume":"94","author":"B Chen","year":"2023","unstructured":"Chen B, Gomez-Figueroa E, Redenbaugh V, Francis A, Satukijchai C, Wu Y, et al. Do Early Relapses Predict the Risk of Long-Term Relapsing Disease in an Adult and Paediatric Cohort with MOGAD? Ann Neurol. 2023;94:508\u201317.","journal-title":"Ann Neurol"},{"key":"3108_CR137","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1177\/1352458515591071","volume":"22","author":"\u00c1 Cobo-Calvo","year":"2016","unstructured":"Cobo-Calvo \u00c1, Sep\u00falveda M, Bernard-Valnet R, Ruiz A, Brassat D, Mart\u00ednez-Y\u00e9lamos S, et al. Antibodies to myelin oligodendrocyte glycoprotein in aquaporin 4 antibody seronegative longitudinally extensive transverse myelitis: Clinical and prognostic implications. Mult Scler. 2016;22:312\u20139.","journal-title":"Mult Scler"},{"key":"3108_CR138","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1007\/s00415-016-8147-7","volume":"263","author":"M Sep\u00falveda","year":"2016","unstructured":"Sep\u00falveda M, Armangue T, Martinez-Hernandez E, Arrambide G, Sola-Valls N, Sabater L, et al. Clinical spectrum associated with MOG autoimmunity in adults: significance of sharing rodent MOG epitopes. J Neurol. 2016;263:1349\u201360.","journal-title":"J Neurol"},{"key":"3108_CR139","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2020.577467","volume":"351","author":"T Akaishi","year":"2021","unstructured":"Akaishi T, Misu T, Takahashi T, Takai Y, Nishiyama S, Fujimori J, et al. Progression pattern of neurological disability with respect to clinical attacks in anti-MOG antibody-associated disorders. J Neuroimmunol. 2021;351:577467.","journal-title":"J Neuroimmunol"},{"key":"3108_CR140","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1136\/jnnp-2017-315998","volume":"88","author":"JW Hyun","year":"2017","unstructured":"Hyun JW, Woodhall MR, Kim SH, Jeong IH, Kong B, Kim G, et al. Longitudinal analysis of myelin oligodendrocyte glycoprotein antibodies in CNS inflammatory diseases. J Neurol Neurosurg Psychiatry. 2017;88:811\u20137.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"3108_CR141","doi-asserted-by":"publisher","unstructured":"Liyanage G, Trewin BP, Lopez JA, Andersen J, Tea F, Merheb V, et al. The MOG antibody non-P42 epitope is predictive of a relapsing course in MOG antibody-associated disease. J Neurol Neurosurg Psychiatry. 2024. https:\/\/doi.org\/10.1136\/jnnp-2023-332851. [Epub ahead of print].","DOI":"10.1136\/jnnp-2023-332851"},{"key":"3108_CR142","doi-asserted-by":"publisher","first-page":"3565","DOI":"10.1007\/s00415-020-10026-y","volume":"267","author":"DH Whittam","year":"2020","unstructured":"Whittam DH, Karthikeayan V, Gibbons E, Kneen R, Chanatre S, Ciccarelli O, et al. Treatment of MOG antibody associated disorders: results of an international survey. J Neurol. 2020;267:3565\u201377.","journal-title":"J Neurol"},{"key":"3108_CR143","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1056\/NEJM199202273260901","volume":"326","author":"RW Beck","year":"1992","unstructured":"Beck RW, Cleary PA, Anderson MM Jr, Keltner JL, Shults WT, Kaufman DI, et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group. N Engl J Med. 1992;326:581\u20138.","journal-title":"N Engl J Med"},{"key":"3108_CR144","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1001\/jamaophthalmol.2017.6757","volume":"136","author":"JJ Chen","year":"2018","unstructured":"Chen JJ, Tobin WO, Majed M, Jitprapaikulsan J, Fryer JP, Leavitt JA, et al. Prevalence of Myelin Oligodendrocyte Glycoprotein and Aquaporin-4-IgG in Patients in the Optic Neuritis Treatment Trial. JAMA Ophthalmol. 2018;136:419\u201322.","journal-title":"JAMA Ophthalmol"},{"key":"3108_CR145","doi-asserted-by":"crossref","unstructured":"Nosadini M, Eyre M, Giacomini T, Valeriani M, Della Corte M, Pratic\u00f2 AD, et al. Early Immunotherapy and Longer Corticosteroid Treatment Are Associated With Lower Risk of Relapsing Disease Course in Pediatric MOGAD. Neurol Neuroimmunol Neuroinflamm. 2023;10:e200065.","DOI":"10.1212\/NXI.0000000000200065"},{"key":"3108_CR146","doi-asserted-by":"publisher","first-page":"e572","DOI":"10.1212\/NXI.0000000000000572","volume":"6","author":"H Stiebel-Kalish","year":"2019","unstructured":"Stiebel-Kalish H, Hellmann MA, Mimouni M, Paul F, Bialer O, Bach M, et al. Does time equal vision in the acute treatment of a cohort of AQP4 and MOG optic neuritis? Neurol Neuroimmunol Neuroinflammation. 2019;6:e572.","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"key":"3108_CR147","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1136\/jnnp-2022-330360","volume":"94","author":"J Rode","year":"2023","unstructured":"Rode J, Pique J, Maarouf A, Ayrignac X, Bourre B, Ciron J, et al. Time to steroids impacts visual outcome of optic neuritis in MOGAD. J Neurol Neurosurg Psychiatry. 2023;94:309\u201313.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"3108_CR148","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/1710-1492-9-30","volume":"9","author":"D Liu","year":"2013","unstructured":"Liu D, Ahmet A, Ward L, Krishnamoorthy P, Mandelcorn ED, Leigh R, et al. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy, Asthma Clin Immunol. 2013;9:30.","journal-title":"Allergy, Asthma Clin Immunol"},{"key":"3108_CR149","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1001\/jamaneurol.2022.0489","volume":"79","author":"JJ Chen","year":"2022","unstructured":"Chen JJ, Huda S, Hacohen Y, Levy M, Lotan I, Wilf-Yarkoni A, et al. Association of Maintenance Intravenous Immunoglobulin With Prevention of Relapse in Adult Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease. JAMA Neurol. 2022;79:518\u201325.","journal-title":"JAMA Neurol"},{"key":"3108_CR150","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102251","volume":"44","author":"DH Whittam","year":"2020","unstructured":"Whittam DH, Cobo-Calvo A, Lopez-Chiriboga AS, Pardo S, Gornall M, Cicconi S, et al. Treatment of MOG-IgG-associated disorder with rituximab: An international study of 121 patients. Mult Scler Relat Disord. 2020;44:102251.","journal-title":"Mult Scler Relat Disord"},{"key":"3108_CR151","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1002\/ana.25648","volume":"87","author":"P Durozard","year":"2020","unstructured":"Durozard P, Rico A, Boutiere C, Maarouf A, Lacroix R, Cointe S, et al. Comparison of the Response to Rituximab between Myelin Oligodendrocyte Glycoprotein and Aquaporin-4 Antibody Diseases. Ann Neurol. 2020;87:256.","journal-title":"Ann Neurol"},{"key":"3108_CR152","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1136\/jnnp-2022-330086","volume":"94","author":"G Spagni","year":"2023","unstructured":"Spagni G, Sun B, Monte G, Sechi E, Iorio R, Evoli A, et al. Efficacy and safety of rituximab in myelin oligodendrocyte glycoprotein antibody-associated disorders compared with neuromyelitis optica spectrum disorder: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2023;94:62\u20139.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"3108_CR153","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-022-02612-6","volume":"22","author":"SO Seneviratne","year":"2022","unstructured":"Seneviratne SO, Marriott M, Ramanathan S, Yeh W, Brilot-Turville F, Butzkueven H, et al. Failure of alemtuzumab therapy in three patients with MOG antibody associated disease. BMC Neurol. 2022;22:84.","journal-title":"BMC Neurol"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-024-03108-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-024-03108-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-024-03108-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T23:03:38Z","timestamp":1724799818000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-024-03108-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,23]]},"references-count":153,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["3108"],"URL":"https:\/\/doi.org\/10.1038\/s41433-024-03108-y","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,23]]},"assertion":[{"value":"19 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"NJ and ML have no financial disclosures to report. RD has received research funding from the Star Scientific Foundation, The Trish Multiple Sclerosis Research Foundation, Multiple Sclerosis Research Australia, the Petre Foundation and the NHMRC (Australia; Investigator Grant). He has also received honoraria from Biogen Idec as an invited speaker, and is on the IDMC for a Roche RCT in paediatric MS. He is on the medical advisory board (non-remunerated position) of The MOG Project. SR has received research funding from the National Health and Medical Research Council (NHMRC, Australia), the Petre Foundation, the Brain Foundation, the Royal Australasian College of Physicians, and the University of Sydney. She is supported by an NHMRC Investigator Grant (GNT2008339). She serves as a consultant on an advisory board for UCB and Limbic Neurology, and has been an invited speaker for educational\/research sessions coordinated by Biogen, Alexion, Novartis, Excemed and Limbic Neurology. She is on the medical advisory boards (non-remunerated positions) of The MOG Project and the Sumaira Foundation.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}